Devyser wins tender in Italy worth approximately SEK 5.7 million – doubling test volumes compared with previous agreement
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
In this case study, Dr. Papasavva describes her laboratory’s journey from traditional thalassemia testing to state-of-the-art NGS technology and what a difference this has made in their daily work.
Whitepaper
This whitepaper explores the diagnostic
challenges posed by the α3.7 and α4.2 deletions in
alpha thalassemia testing and the opportunities to
overcome the limitations of traditional methods.
In this whitepaper, you will learn:
• The molecular basis and clinical implications of the
α3.7 and α4.2 deletions.
• Key challenges in the detection of these deletions
using traditional diagnostic methods.
• Advances in NGS technologies and their impact on
thalassemia diagnostics.
• The need for integrated data analysis software to
enable accessibility to thalassemia genetic testing.
Devyser Diagnostics AB, through its Italian subsidiary, has been awarded a renewed tender by...
Read More
Devyser announced that One Lambda™ Devyser Accept cfDNA, its test for monitoring kidney transplant...
Read More
Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial...
Read More
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More